Miglio and graduated in Pharmacy in 1959 at the University of Pavia; immediately afterwards, in 1960, he was hired by Sandoz Italia as a scientific representative of the drug. Following his successful performances, he was appointed marketing director in 1972; between 1975 and 1978 he was assigned international responsibility in South America, where he reorganized and managed the pharmaceutical division of Sandoz Argentina. Meeting in Pavia with Miglio, president of Mipharm, a leading company in the sector in Italy and abroad
04 June 2015 – The Pavia Province
P
AVIA. There is talk of generic drugs and the pharmaceutical industry this afternoon at 6 pm in the great hall of the Cairoli college, which invited Giuseppe Miglio, president of Mipharm, a leading Milanese company in the production of high-quality generic drugs made in Italy. Not only that, Mipharm can currently boast the following strengths on the pharmaceutical market: solid experience in products destined for the US market (Fda certification and four certified production lines), strong diversification strategy; very high exports: in 2014, the 62% of production was destined abroad with as many as 14.6% destined for the USA.
Miglio explains: «The generic drug sector in Italy is performing well; he is one of the very few who still shoot in the country despite the crisis. In Italy, the market share of generic drugs stands at 20%; in Germany and the USA it reaches 50%. The reason is clear: the generic in Italy was born 15 years ago with a delay of several years compared to other European countries and is developing. Savings and benefits are very evident: the consumer would have a drug with the same production and the same quality as the branded product (brand name), but with a lower cost and with positive repercussions on family finances». What is the attitude of the Italian consumer towards generic drugs? «The attitude of the Italian consumer is positive; this is demonstrated by the sales trend which in the case of the generic has constant growth while the branded drug remains stable without growth». Is the pharmaceutical industry an attractive sector for young graduates? What prospects does it offer? «As already said – replies Miglio – it is one of the very few sectors that creates jobs in our country and offers prospects for young and prepared young graduates».
Student of the Borromeo college, Miglio and graduated in Pharmacy in 1959 at the University of Pavia; immediately afterwards, in 1960, he was hired by Sandoz Italia as a scientific representative of the drug. Following his successful performances, he was appointed marketing director in 1972; between 1975 and 1978 he was assigned international responsibility in South America, where he reorganized and managed the pharmaceutical division of Sandoz Argentina.
During this period, Miglio obtained a master's degree in economics and commerce from the University of Buenos Aires and a master's degree from Insead of Fontainebleau (France). In 1979, Miglio was called back to Italy as director of the pharmaceutical division of Sandoz Italia which, under his leadership, rapidly achieved exceptional growth.
In 1984 he was appointed vi-director general of Sandoz Prodotti Farmaceutici spa, and finally he was appointed president and managing director of Sandoz Holding Italia, i.e. the leader of the Sandoz group in Italy.
Despite the great difficulties of the Italian market, he led the company to extraordinary growth within a few years. During his tenure, Sandoz entered the very exclusive club of companies with a turnover of over 1,000 billion lire, and became one of Italy's most dynamic multinationals.
On 2 June 1990 Miglio was appointed Cavaliere del Lavoro by the President of the Republic Francesco Cossiga.
In 1997, almost at the end of his working career, Miglio - considering the pressure coming from the Italian labor market - decided to start an innovative company in the pharmaceutical sector. After leaving Novartis, he decided to set up a new company, Mipharm, acquiring the Sandoz manufacturing plant in Italy in order to continue and preserve the manufacturing tradition of Sandoz in Milan.
The objective of the new company is to establish a new concept of industrial relations, production and marketing in the pharmaceutical sector. Mipharm's vision is focused on new technologies and technological innovation at the service of medicines. In June
2009, after the sale of the commercial marketing branch to the Swiss group Novartis, Mipharm concentrated its resources on the development and production of generic drugs, as well as the new supergeneric drugs which will play a growing and vital role in the Italian and foreign pharmaceutical market.
